Hematologic, clinical, and cytogenetic analysis in 109 patients with primary myelodysplastic syndrome

Parlier, V.; Melle, Guy van; Beris, P.; Schmidt, P.M.; Tobler, Andreas; Haller, E.; Bellomo, M. Jotterand

doi:10.1016/0165-4608(94)90094-9

Cited by 66 publications

(31 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…34 In four of the six cases of MDS RA, the translocation was found in association with del(5q). [30][31][32][33] These findings, therefore, suggest that this abnormality may be preferentially associated with deletion of 5q− in cases with the clinical characteristics of 5q− syndrome. The single case of ALL, also, showed a deletion of 5q as a secondary change as part of a complex evolving karyotype.…”

Section: A Overall Cases In 'Other' Groupmentioning

confidence: 74%

See 1 more Smart Citation

Ten novel 11q23 chromosomal partner sites

Cuneo²,

et al. 1998

View full text Add to dashboard Cite

The MLL gene located at 11q23 has been described as a 'promiscuous' gene due its involvement with a large number of genetic partners. The EU Concerted Action Workshop on 11q23 provided 550 cases for study of which 82 showed abnormalities which did not involve the established translocations or deletion of 11q23. In these 'other' cases, which included inversions and duplications, 11q23 was found to be involved with 25 chromosome partners of which 10 had not been previously reported. These were 1q31, 4p11, 6q13, 8q21, 10q22, 10q25, 11q11, 11q21, 13q34 and 18q23. This study demonstrated the value of the Workshop, in confirming the diversity of chromosomal partner sites involved with 11q23 and in the identification of new partners.

show abstract

Section: A Overall Cases In 'Other' Groupmentioning

confidence: 74%

“…All except one were AML or MDS. [28][29][30][31][32][33] The remaining one was an ALL. 34 In four of the six cases of MDS RA, the translocation was found in association with del(5q).…”

Section: A Overall Cases In 'Other' Groupmentioning

confidence: 99%

Ten novel 11q23 chromosomal partner sites

Cuneo²,

et al. 1998

View full text Add to dashboard Cite

show abstract

“…[3][4][5][6][7][8][9][10][11][12][13][14][15][18][19][20][21][22][23][24][25][26] Chromosome defects were more common in RAEB and RAEB-t than in RARS and RA. Deletions or gains of entire chromosomes had an incidence of 60.4% and translocations of only 1.8%.…”

Section: Discussionmentioning

confidence: 99%

Incidence and prognostic significance of karyotype abnormalities in de novo primary myelodysplastic syndromes: a study on 331 patients from a single institution

et al. 2005

View full text Add to dashboard Cite

The impact of clinical parameters, International Prognostic Scoring System (IPSS) scores/cytogenetic categories, and some single cytogenetic defects on overall survival (OS) and time to myelodysplastic syndromes (MDS)/AML progression (progression-free interval (PFI)) was evaluated in 331 MDS patients. Statistical analysis demonstrated that OS and PFI were significantly affected by all these parameters. Since single 7q-showed a better survival than the poor IPSS cytogenetic category (P ¼ 0.009), it was considered as a new prognostic entity ('modified IPSS categories'). In multivariate analysis OS was significantly influenced by age, marrow blast cell percentage, number of cytopenias and either modified or standard IPSS cytogenetic categories; hazard ratios for MDS/AML progression were influenced by all the former, except for age and cytopenias. Multivariate analysis of del (7)(q31q35) confirmed the results of univariate analysis, but the Akaike Information Criterion showed no difference in evaluating OS and PFI between the modified and standard IPSS cytogenetic grouping. In conclusion, (i) chromosome defects as grouped by IPSS and blast cell percentage are the most relevant parameters for predicting OS and PFI; (ii) the prognostic power of the IPSS cytogenetic grouping is not ameliorated by the introduction of del(7)(q31q35) as a new entity; (iii) complex karyotypes have a prognostic value independent of blast cell percentage.

show abstract

“…In patients with myelodysplastic syndromes (MDSs), the chromosome abnormality not only confirms the clonality of the disease, [1][2][3] but also predicts the likelihood of progression into acute myeloid leukemia (AML) and overall survival (OS). [4][5][6][7][8][9][10][11][12][13][14][15][16] In 1997, the international prognostic scoring system (IPSS) has further emphasized that karyotype is one of the most important prognostic indicators in MDS and can be used along with bone marrow blast cell percentage and number/degree of peripheral cytopenia to subdivide patients into four subgroups having distinct clinical outcomes.…”

Section: Introductionmentioning

confidence: 99%

“…17,18 However, conventional cytogenetics (CCs) reveals a normal karyotype in about 40-60% of patients. 1,2,[6][7][8][9][10][11][12][13] According to IPSS criteria, a normal chromosome pattern is considered prognostically favorable, even if it does not always indicate a positive clinical outcome. Therefore, new biological indicators are urgently needed in these patients in order to identify individuals at risk for AML evolution.…”

Section: Introductionmentioning

confidence: 99%